The focus of our research is the study of lung cancer treatment. This includes both targeted treatment as well as immunotherapy. Circulating tumor DNA (ctDNA) is a particular focus point and is investigated with respect to its role in predicting treatment effect and identifying the onset of resistance. Furthermore, we investigate the use of ctDNA to identify the mutations causing resistance and thus might represent new treatment targets circumventing resistance. Our major studies include:

-Studies of ctDNA to monitor treatment effect of EGFR and ALK targeted treatment.

-Investigations of the role of ctDNA to study the effect of immunotherapy.

-Studies of our new technique cfCHIP (cell-free chromatin immunoprecipitation) which enables us to measure gene activity in lung tumors by analyzing circulating free DNA in a blood sample.

-Development of new bio-informatic tools to study gene fusions in cancer by analyzing ctDNA.

-National and international studies investigating the role of ctDNA.